Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Applying Low-Intensity Focused Ultrasound in Treating Severe Substance Use Disorder: Tolerability and Effectiveness

30. července 2026 aktualizováno: National Taiwan University Hospital

The goal of this clinical trial is to investigate the safety and efficacy of applying low-intensity focused ultrasound targeting the nucleus accumbens in individuals with opioid or amphetamine use disorders. The main questions it aims to answer is:

- Low-intensity focused ultrasound targeting the nucleus accumbens demonstrates sufficient safety and predictable therapeutic efficacy in individuals with opioid or amphetamine use disorders.

Participants will:

  • Received Low-intensity focused ultrasound neuromodulation once
  • Visit the clinic for checkups and asessment at 1 week, 1 month, 3 months, 6 months, 9 months, 1 year, 1.5 years, and 2 years after received Low-intensity focused ultrasound neuromodulation.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

60

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

  • Tchaj-wan
      • Taipei, Tchaj-wan, 100229
        • Nábor
        • National Taiwan University Hospital
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  • Meets the DSM-5 criteria for opioid use disorder or amphetamine use disorder, with a severity level of severe, and does not currently meet the criteria for in sustained remission;
  • Within 7 days prior to the screening assessment, the participant must have been receiving a stable dose of medication treatment, such as methadone, buprenorphine/naloxone, or naltrexone;
  • Within 7 days prior to the screening assessment, the participant must have abstained from illicit substances and alcohol, and must have a negative urine drug test;
  • The bilateral nucleus accumbens must be clearly identifiable on magnetic resonance imaging (MRI), such that they are sufficient for treatment targeting and for indirect measurement from other anatomical structures;
  • The participant must be able to communicate effectively and express their feelings and experiences during the study procedures;
  • The participant must be willing to comply with the study requirements, including adherence to prescribed medications and cooperation with study visits and assessments.

(The participant must have the capacity to make independent medical decisions, as determined by the clinical team.)

Exclusion Criteria:

  • Presence of neurological disorders or major psychiatric disorders, such as acute-phase schizophrenia spectrum disorder, acute-phase bipolar disorder, acute-phase major depressive disorder, severe cognitive impairment, or recent suicidal ideation or plan;
  • Antisocial personality disorder;
  • Occurrence of major physical health problems within 6 months prior to the trial, including: Cardiovascular or hemodynamic abnormalities, such as heart failure, arrhythmia, tachycardia or bradycardia (>100 bpm or <60 bpm), abnormal systolic blood pressure (>180 mmHg or <90 mmHg), or abnormal diastolic blood pressure (>180 mmHg); Platelet or coagulation abnormalities (INR > 1.5) or current use of medications that may cause anticoagulation, such as warfarin or Avastin; Renal dysfunction (eGFR < 30 mL/min/1.73 m²) or ongoing hemodialysis; Severe infection; Immunocompromised status; History of intracranial hemorrhage, intracranial aneurysm, cerebrovascular events within the past 6 months, or brain tumor; Neurological diseases, such as stroke, epilepsy, Parkinson's disease, dementia, or related disorders; Any other physical illness that, based on clinical evaluation, may pose a significant risk to physical function or life during treatment.
  • Participants who, upon evaluation, are deemed unsuitable for MR-guided focused ultrasound treatment, including those with a low skull density ratio (<0.4), intracranial implants, or energy-absorbing structures or sensitive tissues along the ultrasound beam path that cannot be avoided (such as prior ventriculoperitoneal shunt sites, surgical metal clips, significant calcifications, extensive scarring, or any rigid implants). During the pre-treatment evaluation, a head CT scan will be performed to determine whether the skull density ratio is suitable for focused ultrasound treatment. Based on prior theoretical evidence, an excessively low skull density ratio may reduce the efficiency of MR-guided focused ultrasound and increase the risk of adverse effects, and therefore such participants are considered unsuitable for focused ultrasound treatment.
  • Structural abnormality of either side of the nucleus accumbens;
  • Contraindications to MRI, such as claustrophobia, allergy to MRI contrast agents, or the presence of metallic implants incompatible with MRI;
  • Contraindications to PET imaging, such as allergy to radiopharmaceutical contrast agents;
  • Inability to comply with trial-related instructions, lack of legal/behavioral capacity, or lack of motivation to receive treatment;
  • Pregnancy or breastfeeding;
  • Scalp atrophy or poor wound healing of the scalp;
  • Any other condition that, in the physician's judgment, makes the participant unsuitable for enrollment in the clinical trial.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Dvojnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Experimentální skupina
Přístroj: Low-intensity focused ultrasound
transcranially deliver focal energy into the accumbens nucleus in the brain
Falešný srovnávač: Kontrolní skupina
Přístroj: false stimulus
false stimulus

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Substance craving intensity
Časové okno: Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Using visual analogue scale (VAS) to measure craving intensity, higher score shows greater craving for substance
Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Urinalysis
Časové okno: Before intervention, one week, a month, three months, six months, nine months, a year, one and half year after treatment
Whether urine screening tests are positive for opioids and amphetamines. The intervention will be considered effective if the positivity rate decreases by 50% one month after the intervention compared with the time of intervention.
Before intervention, one week, a month, three months, six months, nine months, a year, one and half year after treatment
Severity of Dependence
Časové okno: Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Using Severity of Dependence Scale (SDS) to measure craving intensity, higher score shows greater severity of Dependence
Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Stimulant Relapse Risk
Časové okno: Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Using Stimulant Relapse Risk Scale (SRRS) to measure craving intensity, higher score shows higher stimulant relapse risk
Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Mental health state
Časové okno: Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Using Patient Health Questionnaire (PHQ-9) to measure participants' mental health state, greater scores of these scales shows worse mental health state.
Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Executive function assessment
Časové okno: Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Using Behavior Rating Inventory of Executive Function (BRIEF) to assess how well executive function of participants is.
Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Neuropsychological function assessment
Časové okno: Before intervention, three months, six months, a year, two year after treatment
Using Cambridge Gambling Task (CGT) to assess Neuropsychological function since the intervention is to nucleus accumbens and could potentially affect Neuropsychological function.
Before intervention, three months, six months, a year, two year after treatment
functional Magnetic Resonance Imaging
Časové okno: Before intervention, 24hours, a month, three months after treatment
Because the nucleus accumbens, the intervention target, may be involved in craving, functional magnetic resonance imaging (fMRI) will be used to assess changes in brain activation during the craving task before and after treatment.
Before intervention, 24hours, a month, three months after treatment
Positron Emission Tomography
Časové okno: Before intervention, a month after treatment
Because neuromodulation may affect metabolic activity in the nucleus accumbens, positron emission tomography (PET) will be used to measure cerebral metabolism and compare changes before and after the intervention.
Before intervention, a month after treatment
Anxiety state
Časové okno: Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Using Hamilton Anxiety Rating Scale (HAM-A), and Generalized Anxiety Disorder questionnaire(GAD-7) to measure participants' anxiety state, greater scores of these scales shows worse anxiety state.
Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Depression state
Časové okno: Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Using Hamilton Depression Rating Scale (HAM-D), to measure participants' mental health state, greater scores of these scales shows worse depression state.
Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Attendtion state
Časové okno: Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Using Adult ADHD Self-Report Scale (ASRS) to assess how well attention state of participants is.
Before intervention, one week, a month, three months, six months, nine months, a year, one and half year and two years after treatment
Working memory capacity
Časové okno: Before intervention, three months, six months, a year, two year after treatment
Using N-back test to assess working memory capacity since the intervention is to nucleus accumbens and could potentially affect Neuropsychological function.
Before intervention, three months, six months, a year, two year after treatment

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

National Taiwan University Hospital

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

1. ledna 2025

Primární dokončení (Odhadovaný)

31. prosince 2030

Dokončení studie (Odhadovaný)

31. prosince 2030

Termíny zápisu do studia

První předloženo

12. března 2026

První předloženo, které splnilo kritéria kontroly kvality

27. července 2026

První zveřejněno (Aktuální)

29. července 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

31. července 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

30. července 2026

Naposledy ověřeno

1. července 2026

Více informací

Termíny související s touto studií

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • 202404026DINC

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NEROZHODNÝ

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit